Cenix and Instituto de Medicina Molecular, AstraZeneca and Cellectricon, Kreatech Biotechnology and Ambion, National Institute of Advanced Industrial Science and Technology in Tokyo

Jul 04, 2005

Premium

Cenix, IMM Develop RNAi Screen for Malaria; Seek Funding for Larger Assay

Researchers at the Instituto de Medicina Molecular in Lisbon, Portugal, and Cenix Bioscience hjave developed an RNAi screen for malaria genes that may lead to better anti-malarial therapeutics, IMM and Cenix said last week in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Breakthrough Prize Winners Announced

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

Misuse of Genetic Research

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Not Quite the Ivy League Gene

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

This Week in Nature

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Main menu